G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II–IV
- 1 July 2003
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 32 (2) , 217-223
- https://doi.org/10.1038/sj.bmt.1704108
Abstract
The effect of granulocyte colony-stimulating factor (G-CSF), given after transplantation, was studied in 155 patients transplanted with haematopoietic stem cells (HSCT) from HLA-identical sibling donors at Huddinge University Hospital between 1993 and 2001. Only patients with haematological malignancies were included. Conditioning consisted of total-body irradiation in 118 and busulphan in 37 patients. They were all given methotrexate combined with cyclosporine as graft-versus-host disease (GVHD) prophylaxis. Of the 155 patients, 66 (43%) received G-CSF after HSCT. Those given G-CSF had a significantly shorter time to neutrophil engraftment (Pvs 9%, PP=0.06) in the two groups, respectively. The cumulative incidences of transplant-related mortality, survival, chronic GVHD, relapse and relapse-free survival were similar in both groups. In conclusion, G-CSF given after HLA-identical sibling HSCT was associated with a higher risk of grades II–IV acute GVHD, but not transplant-related mortality.Keywords
This publication has 35 references indexed in Scilit:
- Definitions of Cytomegalovirus Infection and Disease in Transplant RecipientsClinical Infectious Diseases, 2002
- A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantationBone Marrow Transplantation, 1999
- Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemiaBone Marrow Transplantation, 1999
- Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donorsBone Marrow Transplantation, 1999
- Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrowBone Marrow Transplantation, 1998
- Allogeneic marrow transplantation and the use of hematopoietic growth factorsThe International Journal of Cell Cloning, 1995
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipientsJournal of Antimicrobial Chemotherapy, 1986
- Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reactionJournal of the American Academy of Dermatology, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958